FcRn Antagonists: Transformative Potential in Treating Generalized Myasthenia Gravis
Webcast
0.75 AMA PRA Category 1 Credit™ ...OVERVIEW
FcRn Antagonists: Transformative Potential in Treating Generalized Myasthenia Gravis is organized by Prime Education, LLC and will be held from Aug 29, 2024 - Aug 28, 2025.
Release Date: August 29, 2024
Expiration Date: August 28, 2025
Description:
Patients with generalized myasthenia gravis (gMG), a rare and chronic autoimmune disease, experience severe fatigue and muscle weakness that negatively impact their daily lives. Greater understanding of the complex pathophysiology of gMG has led to a rapidly evolving treatment landscape, including targeted therapies providing a more individualized and effective approach. Neonatal Fc receptor (FcRn) antagonists are the latest class of medications to receive approval for gMG, and several recent phase 3 trials are likely to result in a greater selection of available FcRn-targeting therapies.
In this first of two videos, join two experts in a discussion covering the pathophysiology of gMG, current treatment modalities and management strategies, and an in-depth look at the role of FcRn antagonism, including evaluation of the latest clinical evidence for approved and emerging FcRn antagonists.
You will also gain immediate access to downloadable evidence and a concise, point-of-care resource to reference in your daily practice.
This activity is delivered in partnership with the Muscular Dystrophy Association (MDA).
Learining Objectives:
- Describe the immune-mediated pathophysiology of gMG
- Summarize the roles and limitations of surgical interventions and maintenance therapies in gMG, considering administration, onset of action, toxicities, and patient-level factors
- Evaluate recent clinical and real-world evidence on novel and emerging FcRn antagonists for gMG, including evidence related to special patient populations
ACCREDITATION & CREDITS
Accreditation:
Joint Accreditation Statement
In support of improving patient care, PRIME® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Credit Designation Statement
PRIME® designates this Enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Physician Assistant Accreditation Statement
PRIME® has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioner Accreditation Statement
PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 0.75 contact hour (which includes 0.5 hour of pharmacology).
Pharmacist Accreditation Statement
This Knowledge-based activity has been approved for 0.75 contact hour (0 CEUs) by PRIME® for pharmacists. The Universal Activity Number for this activity is JA0007144-0000-24-206-H01-P . Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity by providing your NABP ID & DOB, which must be submitted within 60 days of completion. Pharmacists with questions can contact NABP customer service (help@nabp.pharmacy).
Nurse Accreditation Statement
PRIME® designates this activity for 0.75 contact hour.
TARGET AUDIENCE
NursingPharmacistNeurologistsNursesNurse PractitionersSPECIALITIES
Neurology
Quick Links